Thus, the well-controlled combination treatment of SP1, MYC, and HIF1A inhibitors for cancer cells should keep the expression under control of the genes whose overexpression is necessary to satisfy the enormous appetite of cancer cells for their fast growth and renewal and should suppress cancer progression, whereas it should not induce a great negative impact on normal cells that do not require enormous amounts of energy and materials for their survival. This evidence concerns the gene HIF1A and cancer.